Pfizer Out-Licenses Clinical-Stage Cancer Antibody to VLST
By Heathe Cartwright
Pharma Deals Review: Vol 2012 Issue 9 (Table of Contents)
Published: 26 Sep-2012
DOI: 10.3833/pdr.v2012.i9.1807 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Seattle-based biotech VLST has moved into oncology and the clinical development arena by licensing CP-870,893, an anti-CD40 monoclonal antibody, from Pfizer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS